Fig. 3 | Scientific Reports

Fig. 3

From: Association of early vedolizumab trough levels with clinical, biochemical, endoscopic response and drug optimization during maintenance therapy in patients with inflammatory bowel diseases

Fig. 3

Long-term outcome achievement rates, stratified by W14 VTL quartiles. Bar plots showing the proportion of (A) W54 BioRES[FC] and (B) drug optimization during maintenance therapy across W14 VTL quartiles. BioRES, biochemical response; CD, Crohn’s disease; FC, fecal calprotectin; Q, quartile; VTL, vedolizumab trough level; W, weeks.

Back to article page